The Risk Management Plans (RMPs) are comprehensive documents submitted as part of the application dossiers for market approval of medicinal products. The RMP summaries contain information on the medicinal products′ safety profiles and explain the measures that are taken in order to further investigate and follow the risks as well as to prevent or minimise them.
The RMP summaries published are concise documents and do not claim to be exhaustive. As the RMPs are international documents, their summaries might differ from the content in the product information («Arzneimittelinformation») approved and published in Switzerland, e.g. by mentioning risks occurring in populations or indications not included in the Swiss authorisations. Please note that the reference documents, which are valid and relevant for the effective and safe use of medicinal products in Switzerland, are the «Arzneimittelinformationen» (see www.swissmedicinfo.ch) approved and authorised by Swissmedic.
The Marketing Authorisation Holders are responsible for the accuracy and correctness of the content of the here published RMP summaries.
Suche nach Präparatenamen
Results
0 Results found
Documents
Sorted...
Sorted by active substance
A - C
autologus anti CD 19 transduced CD3 cells (Tecartus®) RMP Summary (PDF, 121 kB, 30.09.2023)Version 3.0
Complexus toxini botulinici A et Haemagglutinini (Alluzience®) RMP Summary (PDF, 141 kB, 24.01.2022)Version 7.6
D - F
Diphtheria-2/Tetanus/5AC Pertussis Vaccine (Adacel®) RMP Summary (PDF, 122 kB, 17.10.2022)Version 5.0
Emtricitabine Rilpivirine Tenofovir Alafenamide (Odefsey®): RMP (PDF, 104 kB, 01.05.2021)Version 3.0
Emtricitabine / Tenofovir Disoproxil Fumarate (Truvada®) RMP Summary (PDF, 124 kB, 31.03.2023)Version 1.0
G - K
Humaner Papillomavirus-Impfstoff 9-valent (Gardasil 9®): RMP summary (PDF, 88 kB, 08.09.2023)Version 5.1
HYNIC-D-Phe 1 Tyr 3- octeotridum_trifluoroacetum (Tektrotyd®): RMP summary (PDF, 201 kB, 30.11.2015)Version 1.0
L - N
Lutetium vipivotide tetraxetan (Pluvicto/Pluvicto CA®) RMP Summary (PDF, 265 kB, 11.10.2023)Version 1.2
measles, mumps, rubella and varicella virus (Priorix Tetra®): RMP Summary (PDF, 186 kB, 01.12.2019)Version 1.0
Meningoccal groups A,C,W-135 and Y conjugate vaccine (Menveo®) RMP Summary (PDF, 184 kB, 06.03.2023)Version 1.0
MENINGOCOCCAL POLYSACCHARIDE A, C, W-135 AND Y (Menquadfi)®) RMP Summary (PDF, 127 kB, 10.07.2023)Version 1.2
Methylthioninium chloride (Methylthioninumchlorid Proveblue®) RMP Summary (PDF, 175 kB, 29.01.2024)Version 3.2
O - R
Quatrivalent Influenza Vaccine_cell based (Flucelvax Tetra®) RMP Summary (PDF, 820 kB, 23.01.2023)Version 2.0
Quadrivalent Recombinant Influenca Vaccine (Supemtek®) RMP Summary (PDF, 163 kB, 22.03.2021)Version 1.0
Pertuzumab_Trastuzumab (Phesgo®) RMP Summary-rmpsummary20210607 (PDF, 395 kB, 07.06.2021)Version 1.0
Pneumococcal Polysaccharide Conjugate Vaccine (Prevenar13)® RMP Summary (PDF, 111 kB, 12.03.2024)Version 1.0
Pneumoccocal polysaccharide conjugate vaccine (Vaxneuvance®) RMP Summary (PDF, 86 kB, 31.03.2023)Version 1.0
S - U
Tepotinibum/Tepotinibi Hydrochloridum Monohydricum (Tepmetko®) RMP Summary (PDF, 192 kB, 20.11.2022)Version 5.0
V - Z
Sorted...
Sorted by product name
A - C
Diphtheria-2/Tetanus/5AC Pertussis Vaccine (Adacel®) RMP Summary (PDF, 122 kB, 17.10.2022)Version 5.0
Complexus toxini botulinici A et Haemagglutinini (Alluzience®) RMP Summary (PDF, 141 kB, 24.01.2022)Version 7.6
D - F
Complexus toxini botulinici A et haemagglutinini (Dysport®) RMP Summary (PDF, 152 kB, 24.01.2023)Version 7.6
Quatrivalent Influenza Vaccine_cell based (Flucelvax Tetra®) RMP Summary (PDF, 820 kB, 23.01.2023)Version 2.0
G - K
Humaner Papillomavirus-Impfstoff 9-valent (Gardasil 9®): RMP summary (PDF, 88 kB, 08.09.2023)Version 5.1
L - N
MENINGOCOCCAL POLYSACCHARIDE A, C, W-135 AND Y (Menquadfi)®) RMP Summary (PDF, 127 kB, 10.07.2023)Version 1.2
Meningoccal groups A,C,W-135 and Y conjugate vaccine (Menveo®) RMP Summary (PDF, 184 kB, 06.03.2023)Version 1.0
Methylthioninium chloride (Methylthioninumchlorid Proveblue®) RMP Summary (PDF, 175 kB, 29.01.2024)Version 3.2
O - R
Emtricitabine Rilpivirine Tenofovir Alafenamide (Odefsey®): RMP (PDF, 104 kB, 01.05.2021)Version 3.0
Pertuzumab_Trastuzumab (Phesgo®) RMP Summary-rmpsummary20210607 (PDF, 395 kB, 07.06.2021)Version 1.0
Lutetium vipivotide tetraxetan (Pluvicto/Pluvicto CA®) RMP Summary (PDF, 265 kB, 11.10.2023)Version 1.2
Pneumococcal Polysaccharide Conjugate Vaccine (Prevenar13)® RMP Summary (PDF, 111 kB, 12.03.2024)Version 1.0
measles, mumps, rubella and varicella virus (Priorix Tetra®): RMP Summary (PDF, 186 kB, 01.12.2019)Version 1.0
S - U
Quadrivalent Recombinant Influenca Vaccine (Supemtek®) RMP Summary (PDF, 163 kB, 22.03.2021)Version 1.0
autologus anti CD 19 transduced CD3 cells (Tecartus®) RMP Summary (PDF, 121 kB, 30.09.2023)Version 3.0
HYNIC-D-Phe 1 Tyr 3- octeotridum_trifluoroacetum (Tektrotyd®): RMP summary (PDF, 201 kB, 30.11.2015)Version 1.0
Tepotinibum/Tepotinibi Hydrochloridum Monohydricum (Tepmetko®) RMP Summary (PDF, 192 kB, 20.11.2022)Version 5.0
Emtricitabine / Tenofovir Disoproxil Fumarate (Truvada®) RMP Summary (PDF, 124 kB, 31.03.2023)Version 1.0
Last modification 26.03.2024